CytoDyn Inc.
CYDY- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001175680
No open-market purchases or sales by CytoDyn Inc. insiders were filed in the last 90 days; 6 institutions reported holding it in 13F filings for Q2 2026, worth $35.2K in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding CytoDyn Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 12 | 9 | −3 |
| Shares | 538.7K | 200.5K | −338.2K (−62.8%) |
| Value | $146.5K | $41.2K | −$105.3K (−71.9%) |
New holders (1)
Institutions that held CytoDyn Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Virtue Capital Management, LLC | 45,000 | $12.2K | 0.00% |
Sold out (4)
Institutions that held CytoDyn Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Firsthand Capital Management, Inc. | 222,730 | $60.1K |
| Capital Advantage, Inc. | 91,000 | $24.0K |
| Next Capital Management LLC | 37,500 | $10.1K |
| Monograph Wealth Advisors, LLC | 24,000 | $6.48K |